Investigation announced for Investors in shares of Amgen Inc. (NASDAQ: AMGN) over possible Violations of Securities Laws

An investigation was announced over potential securities laws violations by Amgen Inc. in connection with certain financial statements.

Investors who purchased shares of Amgen Inc. (NASDAQ: AMGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amgen Inc. (NASDAQ: AMGN) concerning whether a series of statements by Amgen Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Thousand Oak, CA based Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Amgen Inc. reported that its annual Total Revenue rose from over $25.42 billion in 2020 to over $25.97 billion in 2021, and that its Net Income declined from over $7.26 billion in 2020 to over $5.89 billion in 2021.
On April 27, 2022, Amgen Inc disclosed in its first quarter 2022 earnings release that "[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service ('IRS')] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company's entities in the United States and the U.S. territory of Puerto Rico" which "seeks to increase Amgen's U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest." Amgen Inc also disclosed that the IRS "notice proposes penalties of approximately $2 billion."

Shares of Amgen Inc. (NASDAQ: AMGN) declined $258.39 per share on April 21, 2022, to $231.15 per share on April 28, 2022.

Those who purchased shares of Amgen Inc. (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.